CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
Status:
Completed
Trial end date:
2019-11-14
Target enrollment:
Participant gender:
Summary
The study investigators' aim is to determine the long term safety and efficacy of Metreleptin
(Myalept,) in promoting amelioration of metabolic abnormalities in patients with all forms of
partial lipodystrophy. Patients will be offered this protocol under the following condition:
Subjects have completed University of Michigan research protocol MB002-014 and have shown
improved clinical benefit as judged by clinical criteria set forth in this protocol.